Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 9

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 3
Chunk 9
---
;                                                                                         
●   the third parties may not properly maintain or defend certain intellectual                                                           
    property rights that may be important to the commercialization of Macrilen™ (macimorelin);                                           
●   the third parties may encounter conflicts of interest, changes in business                                                           
    strategy or other issues which could adversely affect their willingness or ability to fulfill their obligations to us (for example,  
    pharmaceutical companies historically have re-evaluated their priorities following mergers and consolidations, which have been common
    in this industry);                                                                                                                   

12
--

●                                 delays in, or failures to achieve, scale-up to commercial quantities,                               
    or changes to current raw material suppliers or product manufacturers (whether the change is attributable to us or the supplier or
         manufacturer) could delay clinical studies, regulatory submissions and commercialization of Macrilen™ (macimorelin); and     
--------------------------------------------------------------------------------------------------------------------------------------
●   disputes may arise between us and the third parties that could result                                                             
    in the delay or termination of the manufacturing or commercialization of Macrilen™ (macimorelin), resulting in litigation or      
    arbitration that could be time-consuming and expensive, or causing the third parties to act in their own self-interest and not in 
    our interest or those of our shareholders.                                                                                        
 
In addition, the third parties can terminate our agreements with them for a number of reasons based on the terms of the individual agreements that we have entered into with them. If one or more of these agreements were to be terminated, we would be required to devote additional resources to manufacturing and commercializing Macrilen™ (macimorelin).
 
We may be unsuccessful in consummating further out-licensing arrangements for MacrilenTM (macimorelin) on favorable terms and conditions, or we may be significantly delayed in doing so.
 
As part of our product development and commercialization strategy, we are evaluating out-licensing opportunities and other potential strategic options for Macrilen™ (macimorelin) in addition to and taking into account existing License Agreements and commercialization agreements signed with Pharmanovia, MegaPharm Ltd. and ER Kim Pharmaceuticals Bulgaria Eood and NK MEDITECH Ltd. If we elect to collaborate with third parties in respect of macimorelin, we may not be able to negotiate a collaborative arrangement for macimorelin on favorable terms and conditions, if at all. Should any partner fail to successfully commercialize macimorelin, our business, financial condition and results of operations may be adversely affected